Barclays
LEGN icon

Barclays’s Legend Biotech LEGN Stock Holding History

Barclays’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$49.9K – 5228
2022
Q4 		$49.9K Buy
+1,000
New +$48.4K ﹤0.01% 4551

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Matthews International Capital Management
Matthews International Capital Management San Francisco, California $241M AUM 42.66% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
IAMH
IvyRock Asset Management (HK) Sheung Wan, Hong Kong $190M AUM 21.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Barclays's LEGN Position: Q3 2026 in Review

Barclays increased its Legend Biotech (LEGN) stake by 12% in Q3 2026, buying an estimated $431K and bringing the position to 195,523 shares worth $3.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Barclays first reported a position in LEGN in Q1 2022 and has held it in 19 quarters since. The position peaked at $23.6M in Q4 2022. 98 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Barclays held 195,523 shares of Legend Biotech worth $3.89M as of Q3 2026.
  • Barclays bought 20,201 Legend Biotech shares in Q3 2026, an estimated $431K.
  • Legend Biotech made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2177 holding.
  • Barclays first reported a position in Legend Biotech in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Legend Biotech position peaked at $23.6M in Q4 2022.
  • 98 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.